Published in Vaccine Weekly, February 9th, 2011
Despite advances in therapy, prognosis for non-small cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) remains poor. The late-phase pipeline holds little promise for considerable improvements in patient outcomes however; these drugs are forecast to realize sales of over $3.1 billion by 2019. Many unmet needs remain unfulfilled; therefore significant commercial opportunities...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.